pharmaceutical pricing

Tatiana Andía

Ref Batch
G
Ref Batch Number
5
Country of Reform
Interviewers
Gordon LaForge
Name
Tatiana Andía
Country
Date of Interview
Reform Profile
No
Abstract

In this 2018 interview, Tatiana Andía, now a professor at the University of Los Andes in Bogota, discusses the challenges facing Colombia’s health sector, principles of bureaucratic reform, and her experience as part of the health ministry’s drug price regulation team, whose work triggered a high-stakes showdown with the global pharmaceutical industry that had dramatic, unintended implications for Colombia’s foreign policy. 

Profile

Tatiana Andía was an expert on the political economy of access to medicines conducting PhD dissertation research at the Colombian health ministry when the minister asked her to join a small, upstart team focused on regulating out-of-control pharmaceutical prices. Lowering the cost of drugs was crucial for ensuring the health care system’s financial sustainability, the ministry’s top priority for the sector. 

When Curbing Spending Becomes the Top Priority: Colombia Tries to Balance Health Needs and Fiscal Capacity, 2013-2017

Author
Gordon LaForge
Country of Reform
Abstract

In 2012, Colombia’s public health system was headed for bankruptcy. The country had made significant progress on important public health priorities: expanding immunizations, reducing infant mortality, and attaining near-universal insurance coverage. But a Constitutional Court ruling that the government had to pay for almost all health services and technologies for those it subsidized, combined with rising pharmaceutical prices, was pushing the budget into deficit. Economist Alejandro Gaviria became minister of health and social protection amid that simmering crisis. To contain spiraling costs while enabling the sector to focus on some of its priorities, he worked to create new legislation that would limit the services the government would cover, regulate the drug market, and adjust an incentive structure that had lowered accountability and encouraged excess. In parallel, budget officials in the health ministry, the Ministry of Finance and Public Credit, and the National Planning Department tried to improve financial management of the system in order to increase efficiency and reduce costs. In the end, some of Gaviria’s efforts paid off and the ministry averted immediate insolvency, but as of 2018, the viability of Colombia’s health-care system remained in doubt even as health indicators improved.

Gordon LaForge drafted this case study based on interviews conducted in Bogota, Colombia in September 2018. Case published November 2018.

To view a short version of the case, please click here